Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (clinicaltrials.gov) - Oct 24, 2026 - P1 | N=33 | Recruiting | Sponsor: Washington University School of Medicine | Suspended ➔ Recruiting
Checkpoint inhibition • Enrollment open • Melanoma • Oncology • Solid Tumor • PD-L1
|